BTAI vs NBIX · rev $388.0K vs P/E 45, rev $1.77B
BioXcel Therapeutics Inc (BTAI) versus Neurocrine Biosciences Inc (NBIX) — a side-by-side from cached financials, not a winner call.
BioXcel Therapeutics Inc (BTAI) is a drug manufacturers - specialty & generic company listed on US.
Neurocrine Biosciences Inc (NBIX) is a drug manufacturers - specialty & generic company listed on US.
Latest reported BTAI revenue for 2026-06-30 was $388.0K. Net income was -$27.4M. Revenue was up 88.3% from 2026-03-31 to 2026-06-30. BTAI currently screens at market cap $36.1M.
Latest reported NBIX revenue for 2026-06-30 was $1.77B. Net income was $342.3M. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
BTAI currently screens at market cap $36.1M. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
Not investment advice. Open the BTAI and NBIX stock pages for the full models.
Not investment advice.